Application of fibroblast growth factor 21

A technology of fibroblasts and growth factors, applied in the medical field

Inactive Publication Date: 2016-08-10
THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether FGF21 regulates PPARγ in pulmonary arterial hypertension and pulmonary vascular remodeling is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 The role of FGF21 in hypoxic pulmonary hypertension

[0022] Experimental method: An in vivo model of hypoxic pulmonary hypertension was constructed, and it was confirmed that FGF21 can inhibit pulmonary hypertension and pulmonary vascular remodeling, and FGF21 plays a protective role by up-regulating the expression level of PPARγ.

[0023] This is done with the following steps:

[0024] Male SD rats were randomly divided into A. normoxia group; B. hypoxia group; C. hypoxia+FGF21 intervention group. The rats in the hypoxia group were all placed in an open-hole hypoxic chamber with standard air pressure, and the O2 was kept at 8%-11%, and the CO2 concentration was kept at <3%. They entered the chamber for 8 hours a day. Group C was intraperitoneally injected with FGF21 400ug / Kg 30 minutes before entering the cabin. Continuous modeling for 4 weeks.

[0025] a. Using the PowerLab physiological record analyzer, the right heart catheterization method was used to...

Embodiment 2

[0029] Example 2 Effect of FGF21 on the proliferation and functional changes of pulmonary artery endothelial cells under hypoxia

[0030] Test method: Construct the hypoxia model of endothelial cells in vitro, and confirm the effect of FGF21 on the proliferation and secretion function of endothelial cells.

[0031] This is done with the following steps:

[0032] 1) Purchase human PAECs, use anti-CD31 monoclonal antibody immunofluorescence staining to identify HPAECs and determine cell purity. PAECs of the same generation were randomly divided into: A. normoxia group; B. hypoxia group; C. hypoxia+FGF21 (800ng / ml) group. All hypoxic groups were cultured in a hypoxic incubator under the conditions of 5% CO2, 5% O2, 90% N2, and 37°C. The normoxic group was cultured in a normoxic incubator under the conditions of 5% CO2, 95% N2, and 37°C. After 48 hours of modeling, it was used for follow-up detection.

[0033] 2) CCK-8 staining method was used to detect the proliferation of PA...

Embodiment 3

[0037] Example 3 Effect of FGF21 on Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammatory Response under Hypoxia

[0038] Test method: By constructing the PASMCs hypoxia model, it was confirmed that FGF21 can inhibit the excessive proliferation of PASMCs under hypoxia, and reduce the secretion levels of IL-1, IL-6, and TNF-α inflammatory factors.

[0039] 1) The primary rat PASMCs were obtained by enzymatic digestion, and the purity of PASMCs was identified by immunofluorescence staining with monoclonal antibody against α-SM actin. PASMCs were randomly divided into: A. normoxia group; B. hypoxia group; C. hypoxia + FGF21 (800ng / ml) group. All the hypoxic groups were in the hypoxic incubator according to the conditions of 5% CO2, 5% O2, 90% N2, 37 ℃, and the normoxia group were in the normoxia incubator according to the conditions of 5% CO2, 95% N2, 37 ℃. Conditions, were cultured for 24 hours before index detection.

[0040] 2) CCK-8 staining was used to detect ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of a fibroblast growth factor 21 to preparation of medicine for treating hypoxic pulmonary hypertension, medicine for preventing and treating pulmonary heart disease and medicine for preventing and treating chronic obstructive pulmonary disease. According to the application of the fibroblast growth factor 21, the effects of FGF21 with respect to pulmonary vessel reconstruction resistance, endothelial function damage and vascular inflammation are assessed and verified from the animal integral level and different cell levels. FGF21 can activate a PPAR gamma-relied signal channel by raising the expression level of a peroxisom proliferator to activate the expression level of a receptor gamma, so that the endothelial cell function is improved, proliferation of pulmonary artery endothelial cells and smooth muscle cells of abnormal phenotype is inhibited, secretion of cell factors related to inflammation is inhibited, and thus pulmonary hypertension induced by chronic hypoxia is effectively alleviated or relieved.

Description

technical field [0001] The present invention relates to the field of medical technology, specifically the application of fibroblast growth factor 21. Background technique [0002] Fibroblast growth factor 21 (Fibroblast growth factor 21, FGF21) is a new member of the fibroblast growth factor family, which has a protective effect in regulating glucose and lipid metabolism in diseases related to metabolic disorders such as diabetes and obesity. In recent years, new roles of FGF21 in the cardiovascular system and inflammatory metabolism have been discovered one after another, making it possible to become a promising new vascular protection factor. In the study of systemic vascular diseases, it was found that FGF21 is expressed in cardiomyocytes and endothelial cells, and exogenous administration of FGF21 can protect endothelial cell damage induced by ox-LDL, and intervene in early atherosclerosis. happened. In addition, successive studies have found that FGF21 has an anti-fib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P9/12A61P11/00A61P9/00
CPCA61K38/1825
Inventor 黄晓颖王良兴黄志峰蔡慧平伟东陈阿丽姚丹
Owner THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap